Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NOTCH1
REST API REST API
Homo sapiens
NOTCH1 is differentially expressed in 240 experiments: 108 organism parts: bone marrow, lung, ... (106 more);, 165 disease states: normal, control, ... (163 more);, 96 cell types 334 cell lines 20 compound treatments and 74 other conditions.
Synonyms TAN1
Orthologs notch1b (Danio rerio)   Q3MU93_BOVIN (Bos taurus)   NOTCH1 (2 of 3) (Danio rerio)   Q2L697_CIOIN (Ciona intestinalis)   Q9W737_CHICK (Gallus gallus)   NOTCH1 (3 of 3) (Danio rerio)   Notch1 (Mus musculus)   Notch1 (Rattus norvegicus)   N (Drosophila melanogaster)   notch1 (Xenopus laevis)   NOTCH1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term neuron differentiation, cytosol, plasma membrane, positive regulation of JAK-STAT cascade, embryo development, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, cytoplasm, negative regulation of photoreceptor cell differentiation, somatic stem cell division, regulation of cell proliferation, transcription, DNA-dependent, positive regulation of cell proliferation, membrane, negative regulation of apoptosis, Golgi apparatus, foregut morphogenesis, spermatogenesis, positive regulation of BMP signaling pathway, extracellular region, regulation of neurogenesis, cell fate specification, positive regulation of apoptosis, glial cell differentiation, cell differentiation, acrosomal vesicle, positive regulation of neuroblast proliferation, sequence-specific DNA binding, tissue regeneration, Notch receptor processing, endoderm development, positive regulation of transcription from RNA polymerase II promoter, multicellular organismal development, nucleus, epidermis development, heart development, negative regulation of BMP signaling pathway, regulation of gene expression, response to lipopolysaccharide, chromatin DNA binding, receptor activity, immune response, cell fate commitment, Notch signaling pathway, regulation of developmental process, chromatin binding, axonogenesis, integral to membrane, nucleoplasm, negative regulation of transcription from RNA polymerase II promoter, negative regulation of cell differentiation, regulation of transcription from RNA polymerase II promoter, determination of left/right symmetry, epithelial to mesenchymal transition, endoplasmic reticulum lumen, positive regulation of transcription, DNA-dependent, calcium ion binding, positive regulation of epithelial to mesenchymal transition, response to corticosteroid stimulus, Golgi lumen, negative regulation of myoblast differentiation, secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development, oligodendrocyte differentiation, negative regulation of oligodendrocyte differentiation, positive regulation of astrocyte differentiation, regulation of epithelial cell proliferation involved in prostate gland development, positive regulation of glial cell differentiation, in utero embryonic development, embryonic hindlimb morphogenesis, positive regulation of keratinocyte differentiation, cardiac right ventricle formation, negative regulation of osteoblast differentiation, forebrain development, negative regulation of cell-substrate adhesion, negative regulation of calcium ion-dependent exocytosis, auditory receptor cell fate commitment, gene expression, astrocyte differentiation, hair follicle morphogenesis, positive regulation of transcription of Notch receptor target, keratinocyte differentiation, branching morphogenesis of a tube, positive regulation of epithelial cell proliferation, regulation of epithelial cell proliferation, organ regeneration, negative regulation of neuron differentiation, sprouting angiogenesis, anagen, neural tube development, positive regulation of endothelial cell differentiation, lung development, aortic valve morphogenesis, prostate gland epithelium morphogenesis, negative regulation of cell death, neuron fate commitment, liver development, embryonic limb morphogenesis, negative regulation of canonical Wnt receptor signaling pathway, regulation of somitogenesis, sequence-specific DNA binding transcription factor activity, cell differentiation in spinal cord, core promoter binding, regulation of cardioblast proliferation, negative regulation of glial cell proliferation, Notch signaling pathway involved in regulation of secondary heart field cardioblast proliferation, negative regulation of pro-B cell differentiation, neuronal stem cell maintenance, MAML1-RBP-Jkappa- ICN1 complex, negative regulation of stem cell differentiation, compartment pattern specification
InterPro Term Notch_dom, Notch_NOD_dom, Ankyrin_rpt, Ankyrin_rpt-contain_dom, EGF_extracell, EGF, EGF_3, Notch, Notch_NODP_dom, EGF-like, Notch_1, DUF3454_notch, EGF-like_Ca-bd
UniProt Accession P46531
Gene-Disease Assocation AORTIC VALVE DISEASE
Search EB-eye ENSG00000148400
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (33 experiments)

Factor Value U/D Experiments
MCF-7
2
E-GEOD-3529, E-GEOD-20081
HCC2157
2
E-MTAB-37, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
T84
2
E-GEOD-1474, E-MTAB-37
AsPC1
1
E-MTAB-37
C7H2-R19E7
1
E-GEOD-22152
328 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, E-MEXP-750, E-MEXP-993, ... (44 experiments)

Factor Value U/D Experiments
plasma cell
2
E-GEOD-6691, E-MEXP-2360
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
epithelial cell
1
2
E-GEOD-4483, E-GEOD-10797, E-MEXP-2034
adipocyte
1
E-AFMX-5
basal cell
1
E-GEOD-3998
bronchial epithelial
1
E-AFMX-5
90 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-GEOD-16363, ... (54 experiments)

Factor Value U/D Experiments
control
1
5
E-GEOD-8121, E-GEOD-20295, E-GEOD-20602, E-GEOD-20168, E-GEOD-16728, ... (6 experiments)
colon carcinoma
3
E-MTAB-37, E-GEOD-3726, E-MTAB-62
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
AIDS-KS, HIV+, nodular (late) stage
2
E-MTAB-62, E-MEXP-66
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
159 more value(s).


Compound treatment

studied in E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-GEOD-15811, E-GEOD-4006, ... (13 experiments)

Factor Value U/D Experiments
BCR/ABL1
1
1
E-GEOD-15811
TGF
1
E-GEOD-15205
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
unknown
1
E-GEOD-7307
filtered air
1
E-TABM-127
bacterial endotoxin
1
E-GEOD-3284
14 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
40
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-MEXP-1251, E-GEOD-2034, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-GEOD-2666, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-21138, E-GEOD-1751

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-GEOD-7578, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-GEOD-17476, E-MEXP-421, E-TABM-601, E-MTAB-114

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, E-GEOD-12773, E-TABM-127, ... (9 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-MEXP-1648, E-GEOD-16363, ... (25 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-26495, E-GEOD-1460

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19743, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, ... (7 experiments)

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.321 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM